RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) today announced it has filed revised Financial Statements for the second quarter ending June 30, 2010, due to a technical error in its Consolidated Statement of Cash Flows.

In the Consolidated Statement of Cash Flows filed on August 17, 2010, the figures in the columns under the title "For the six months ended June 30" are correct. The figures under the title "For the three months ended June 30" were erroneous. A corrected Consolidated Statement of Cash Flows has been filed on www.sedar.com. The error and subsequent correction have no impact on the reported Income Statement or Balance Sheet.

BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.

Contacts: BioSyent Inc. Rene C. Goehrum President and CEO (905) 206-0013 (905) 206-1413 (FAX) www.biosyent.com